Nexus Pharmaceuticals Private Limited
About Nexus Pharmaceuticals Private Limited
Data last updated:
Nexus Pharmaceuticals Private Limited was a private limited company based in New Delhi, Delhi, India. The company has been struck off by the Registrar of Companies, typically due to non-filing of annual returns or failure to commence business. It is no longer operational and cannot enter into any legal contracts or agreements. It operated in the support services segment of the services sector. It was incorporated on 18 February 2015.
The company was registered with the Registrar of Companies (ROC), Delhi, under CIN U85100DL2015PTC276859.
The company had an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It was led by directors Vikas Pandey and Upendra Nath Singh.
Its last annual general meeting (AGM) was held on 30 September 2015, and its latest financial statements are for the year ended 31 March 2015. The registered office was at New H.N. A – 187 Old Plot No – 51 Khasra No – 44/7 Ground Floor Hind Vihar Prem Nagar Ph – 3, New Delhi, Delhi, India – 110041.
Company details
Contact details
Nexus Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi.
- Registered AddressNew H.N. A – 187 Old Plot No – 51 Khasra No – 44/7 Ground Floor Hind Vihar Prem Nagar Ph – 3, New Delhi, Delhi, India – 110041
- IndustryService, Other Support Services
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Nexus Pharmaceuticals Private Limited
FY 2015 filings availableFinancial Statement Summary
| Metrics | FY 2014-15 |
|---|---|
| Profit and Loss Statement | |
| Revenue from Operations | |
| Other Income | |
| Total Revenue | |
| Cost of Materials Consumed | |
| Employee Benefit Expense | |
| Finance Costs | |
| Depreciation and Amortisation | |
| Other Expenses | |
| Total Expenses | |
| EBITDA | |
| Profit Before Tax | |
| Tax Expense | |
| Net Profit (PAT) | |
| Balance Sheet | |
| Share Capital | |
| Reserves and Surplus | |
| Net Worth (Total Equity) | |
| Long-term Borrowings | |
| Short-term Borrowings | |
| Trade Payables | |
| Total Liabilities | |
| Fixed Assets | |
| Investments | |
| Inventories | |
| Trade Receivables | |
| Cash and Bank Balance | |
| Total Assets | |
Financial Ratios
| Metrics | FY 2014-15 |
|---|---|
| Profitability | |
| EBITDA Margin | |
| Net Profit Margin | |
| Return on Equity (ROE) | |
| Return on Capital Employed (ROCE) | |
| Return on Assets (ROA) | |
| Liquidity and Debt | |
| Current Ratio | |
| Quick Ratio | |
| Debt-to-Equity Ratio | |
| Interest Coverage Ratio | |
| Efficiency and Growth | |
| Asset Turnover | |
| Receivable Days | |
| Payable Days | |
| Inventory Days | |
| Revenue Growth | |
| Net Profit Growth | |
To see the full financial statements and ratios of Nexus Pharmaceuticals Private Limited, buy the company report.
Board of directors of Nexus Pharmaceuticals Private Limited
Nexus Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Vikas Pandey | Director | 18 Feb 2015 | 11 Years 8 Months | As last reported |
| Upendra Nath Singh | Director | 18 Feb 2015 | 11 Years 8 Months | As last reported |
Legal cases
No court or tribunal cases involving Nexus Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Nexus Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Nexus Pharmaceuticals Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Nexus Pharmaceuticals Private Limited has 2 board changes on record since 2015: 2 appointments. The latest: Upendra Nath Singh was appointed as Director on 18 Feb 2015.
Frequently asked questions
Nexus Pharmaceuticals has a status of "Struck Off" as per MCA records. This means the company has been officially removed from the Register of Companies, typically due to non-filing of annual returns or failure to commence business within one year of incorporation. A struck-off company cannot enter into any legal contracts or agreements, and any dealings with such an entity carry significant legal and financial risk.
Nexus Pharmaceuticals was a private limited company based in New Delhi, Delhi, India. The company worked in other support services, within the service industry. It was incorporated on 18 February 2015 and is registered under CIN U85100DL2015PTC276859. The company has been struck off by the Registrar of Companies and is no longer operational.
Nexus Pharmaceuticals had 2 directors:
- Vikas Pandey - Director
- Upendra Nath Singh - Director
The CIN (Corporate Identification Number) of Nexus Pharmaceuticals is U85100DL2015PTC276859. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
The registered office of Nexus Pharmaceuticals is at New H.N. A – 187 Old Plot No – 51 Khasra No – 447 Ground Floor Hind Vihar Prem Nagar Ph – 3, New Delhi, Delhi, India – 110041.
Nexus Pharmaceuticals was incorporated on 18 February 2015. It is registered with the Registrar of Companies, Delhi.
The latest financial statements of Nexus Pharmaceuticals on record with the MCA are for the year ended 31 March 2015. Its last annual general meeting was held on 30 September 2015. Year-wise statements from 2015 are in the company report.
Nexus Pharmaceuticals operated in the service industry, in the other support services segment. It worked in this industry before it was struck off.
Upendra Nath Singh was appointed as Director on 18 Feb 2015. Vikas Pandey was appointed as Director on 18 Feb 2015.
The compliance status of Nexus Pharmaceuticals is active non-compliant as of 26 August 2026.